A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro.
Maggi, M., Mittelman, S.D., Parmentier, J.H., Colombo, G., Meli, M., Whitmire, J.M., Merrell, D.S., Whitelegge, J., Scotti, C.(2017) Sci Rep 7: 14479-14479
- PubMed: 29101342 
- DOI: 10.1038/s41598-017-15075-4
- Primary Citation of Related Structures:  
5MQ5 - PubMed Abstract: 
L-Asparaginases (ASNases) have been used as first line drugs for paediatric Acute Lymphoblastic Leukaemia (ALL) treatment for more than 40 years. Both the Escherichia coli (EcAII) and Erwinia chrysanthemi (ErAII) type II ASNases currently used in the ...